The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial.
- 2025-08-28
- RCT
- Inflammopharmacology 33(9)
- Mohammad Mahmoudi Azar
- Matin Shirazinia
- Mohsen Nematy
- Vafa Baradaran Rahimi
- Motahare Bateni
- Fateme Tafaghodi Piadeh Gheibi
- Farnood Rajabzadeh
- Ladan Goshayeshi
- Sara Honari
- Mehran Mottahedi
- Vahid Reza Askari
- PubMed: 40877731
- DOI: 10.1007/s10787-025-01919-3
- High evidence
- Clinical
high-density lipoprotein cholesterol (MD: + 3.38 mg/dL; P = 0.019)
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes
- Dose
- 200 mg once a day